Finance entity
Every one of those 1 sits in a single category, markets. Of the tracked stories, 1 of 1 also mention Bank of America, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window.
Last mentioned: 1d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, markets. Of the tracked stories, 1 of 1 also mention Bank of America, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 5.8 for that window. We currently track 1 Finance story that mention Tenaya Therapeutics, all published on September 9, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 33 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Tenaya Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
A Sunday morning research note lifted Wall Street Zen's view on two biotechs—argenx to buy and Tenaya from strong sell to sell—but the market implications diverge sharply. Finance readers get a comparison of a profitable $63 billion rare-disease leader trading at a 38.67 P/E against a $148.75 million speculative gene therapy name at -1.25 P/E.
Tenaya Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
